The Cancer Human Biobank (caHUB): Advancing the Vision of Personalized Medicine

Filling the Infrastructure Gap for Translational Research

Carolyn C. Compton, M.D., Ph.D.
Director, Office of Biorepositories and Biospecimen Research
Acting Director, Office of Technology and Industrial Relations

Presentation to the National Cancer Advisory Board
December 9, 2008
What Is caHUB?

A unique, centralized, non-profit public resource that will ensure the adequate and continuous supply of human biospecimens and associated data of measurable, high quality acquired within an ethical framework.
Ca HUB Discussion in Subcommittee

- What I heard:
  - The connection between this resource and personalized medicine is unclear
    - We will clarify the envisioned roles
  - The strawman solution was too ambitious and comprehensive; a pilot feasibility project (on one specimen type?) is needed
    - Our experience: successful collection of high-quality specimens and data while addressing all ethical, legal and policy challenges cannot be simplified
      - All functional issues must addressed simultaneously
    - Limitation of the number or types of specimen collected does not necessarily simplify the process
      - Most system requirements are identical whether one or one hundred specimens or specimen types are collected
  - We will clarify OBBR’s past, present and on-going “pilot” experience and take the strawman structure off the table
Ca HUB Discussion in Subcommittee

- The need for this resource must be confirmed by a comprehensive market analysis
  - We agree
  - We have completed a first pass survey in NCI’s community and have requested Office of Management and Budget approval for a wider survey

- The business model must be sound and based on the market analysis
  - We agree
  - Efforts to date and planning phase includes domain experts
    - Medical economists
    - Business strategists and systems experts
    - The NIH Public-Private Partnerships Office

- What I also heard:
  - This is important; there are gaps in our existing system
  - We need to do this right
  - We agree
Translational Research Promises to Realize the Vision of Personalized Medicine

Molecular Data  →  Diagnosis / Therapy

PERSONALIZED CANCER CARE

Biospecimen Collection  →  Biospecimen Processing and Banking

Biospecimen Analysis
The Challenge for Translational Research: Biospecimen Resources in the USA Operate in Silos

- Collection, procession, storage procedures differ
- Degree and type of data annotation varies
- Scope and type of patient consent differs
- Access policies are lacking or unknown to potential users
- Materials transfer agreement conditions differ
- Supporting IT structures differ in capacity and functionality

→ WIDE VARIATION IN QUALITY OF SPECIMENS AND DATA
The Step-Wise Process
Towards a National Biospecimen Resource

- NCI Executive Committee approves planning for caHUB
- OBBR begins concept development process for caHUB
- OBBR studies market; risk/benefits; organizational/funding models
- NCI Director asks OBBR to explore plans for a national resource
  - OBBR publishes the NCI Best Practices for Biospecimen Resources
  - Biospecimen Research Network (BRN) is formed
  - OBBR is formed
  - National Biospecimen Network (NBN) Blueprint published
  - National Dialogue on Cancer identifies biospecimens as critically important to post-genomic cancer research
Key principles for a national biobank:

- Standardized biospecimen collection and distribution procedures
- Standardized data sets and data vocabulary
- Integrated information technology system to support all functions
- Harmonized approached to ethical and legal issues
  - Standardized consent, MTAs
- Transparent governance and business models
  - Transparent access policies
- Large well-designed specimen sets
The Importance of Standardized Specimens and the Requirement for a National Biospecimen Resource Is Widely Cited

- Genomics and Personalized Medicine Act of 2007
- Institute Of Medicine Report: *Cancer Biomarkers, 2007*
- Dept. of Health and Human Services, *Personalized Health Care Report, Sept. 2007*
- President’s Council of Advisors on Science and Technology: *Priorities for Personalized Medicine, Sept. 2008*
- President’s Cancer Panel Report, *Maximizing Our Nation’s Investment in Cancer, Sept. 2008*
- Kennedy-Hutchinson Cancer Bill (“War on Cancer, Part II”), 2008
- The NCI By-Pass Budget for FY2010
The USA Lags Behind Other National Initiatives

- **Iceland DeCode Biobank**
  - National; Population-based

- **Estonian Genome Project**
  - National; Population-based

- **UK Biobank**
  - National; Population-based; Ages 45-69

- **GenomEUTwin (Finland)**
  - International; Population-based; Twin cohorts

- **Biobanking and Biomolecular Resources Research Infrastructure**
  - Pan-European; Network of new and existing biobanks (population, twin, case/control)

- **Biobank Japan**
  - National; Hospital patient-based;
  - Focus on common diseases and pharmacogenomic research

- **OnCore UK**
  - National; Cancer Tissue and Blood Repository for research

- **Singapore Tissue Network**
  - National; Tissue and DNA Bank for translational and population research for Singapore
  - Collects, processes, and disseminates tissue samples for specific research projects
• The caHUB vision: standardized specimen and data collections that optimize quality that is fit for the scientific purpose has been and is being piloted
  – The Prostate Cancer SPORE Biomarker Project
  – The Cancer Genome Atlas project

• Issues and solutions: experiences brought to the caHUB Planning Process

• Our answer: Yes, we can
National Biospecimen Network Pilot Study

- Carried out in 2005-2006 among 11 prostate cancer SPORE sites around an inter-SPORE biomarker project in prostate biopsies
- Challenges posed by process variation among study sites:
  - Different procedures for collecting tissues
  - Different procedures for obtaining informed consent
  - Different informatics systems that were not interoperable
  - Lack of information necessary to identify sources of variation
  - Lack of ability/authority of participants to institute procedural changes within their institutions that would be needed to harmonize across sites
- Pilot terminated
- “Rule book” needed: NCI’s Best Practices for Biospecimen Resources
- “Business model” inadequate: academic, collegial, bottom-up
Case Study from The Cancer Genome Atlas (TCGA): Lessons in Biospecimen Challenges and Solutions

- Large-scale team project to explore the full spectrum of cancer-associated genomic changes: coordinated, comprehensive approach
  - Data made available to the broad research community
  - Pilot phase 2006-2009
- Premise: Cancer is a disease of genomic alteration
  - Many alterations remain unknown
- Envisioned benefits (underpinnings for personalized medicine):
  - Elucidate etiologies
  - Provide bases for molecular classification, taxonomy
  - Reveal targets for therapy
  - Provide insights into clinical behavior; prediction, prognosis
TCGA pilot project

- Three different cancers: brain, ovarian and lung
- Biospecimens obtained from a network of retrospective collections at multiple academic medical centers
- Centralized pathology and molecular QC of samples (caHUB model)
- Molecular analyses – 10 platforms
  - RNA and micro-RNA profiling
  - Copy number variation
  - Translocation analysis
  - Epigenetic (methylation) analysis
  - Sequencing
- Clinical data collected for clinical correlation
TCGA Specimen Requirements

- Set by the technical demands of the molecular analysis platforms
- All 10 analysis centers would analyze exactly the same molecules from the same samples from the same patient - all data directly comparable
  - Sufficient quantity to satisfy all platforms
  - Sufficient quality to yield interpretable data on all platforms
- The target number of 500 cases per tumor type: defined depth of analysis and probability of finding genomic changes that occur infrequently (3% level)
TCGA Lessons Learned - Real Numbers

- From responses to original RFI (2006), estimated that all 1500 cases could be acquired from 4-6 sites
- OBBR now working with 54 sites (and counting)
  - Several are outside the USA
- Impossible to reach accrual goals from retrospective collections alone
- Prospective collection instituted – relevant caHUB experience
TCGA Lessons Learned - Real Numbers

- Biobank inventory drop-out rates as high as 95 – 99%
- Molecular QC failure rates for qualifying samples typically 30%

<table>
<thead>
<tr>
<th></th>
<th>Repository 1 (Major Academic Site)</th>
<th>Repository 2 (Major Academic Site)</th>
</tr>
</thead>
<tbody>
<tr>
<td># Frozen samples logged in collection</td>
<td>5000+</td>
<td>1200+</td>
</tr>
<tr>
<td># Samples meeting spec upon detailed review of inventory</td>
<td>1392</td>
<td>120</td>
</tr>
<tr>
<td># Samples meeting physical/pathological specs</td>
<td>174</td>
<td>18</td>
</tr>
</tbody>
</table>

Before full pathology review
Case Study from The Cancer Genome Atlas (TCGA): Lessons in Biospecimen Challenges and Solutions

- Quality of existing samples is typically overestimated by biobanks
- Collection of normal control samples is not routine
- Histological quality does not guarantee molecular quality
- Other important factors:
  - Consent, IRB, HIPAA issues
  - Material Transfer Agreement, Intellectual Property, Authorship, Incentives issues
  - Governance and communication challenges
  - Informatics needs
    - Extraction and transfer of associated clinical data
    - Standards compliance (caBIG™)
  - Costs
Prospective patient consent and tissue collection instituted:

- Protocols designed to maximum qualification of samples
  - Handling appropriate for specimen type and study design

- Protocols started at the source
  - Surgical /OR staff, consent

- Learned that Standard Operating Procedures, training and education required for all aspects
TCGA is now a proven success

- First Nature paper published October 2008
  - Most comprehensive high-quality data set on GBM to date
- Recently approved by BSA for continuation/scale-up
- Specimen accrual recognized as the biggest challenge for the project
  - High-quality data dependent on high-quality analytes from high-quality specimens
  - Strong recommendation to adhere to specimen quality standards
- Bottom line: specimen challenges can be met and are worth the effort, but we don’t already have what we need in our current system

*Lessons learned/solutions developed directly applicable to caHUB*
caHUB

• What it is: a unique, centralized, non-profit public resource that will ensure the adequate and continuous supply of human biospecimens and associated data of measurable, high quality acquired within an ethical framework

• Do we need it?

• What will it do to advance progress?

• What are the next steps?
caHUB Key Concepts

- Scientifically designed collection strategies
- Multiple aliquots of every specimen
- Standardized, annotated collection, processing of all specimens
- Centralized QC and pathology analysis of every specimen
- Rich, standardized data profile for each sample
- Centralized source of normal human specimens
- Provision of tools, resources, training for U.S. biospecimen resources
OBBR Has Developed a Vision in Preparation for Implementation Planning

**caHUB Strategic Planning Process**

**STEP 1: MARKET RESEARCH**
- Project Organization
- Market and Environmental Assessment
  - Initial management
  - Internal Capabilities
  - External Assessment

**STEP 2: PROGRAM DESIGN**
- Program Direction and Strategies
  - Future environmental
- Product and Service Development Plan
  - Scope of product

**Planning Phase**

Step 1: Market research process (lengthy step) already begun

Steps 2 and 3: Approval for FY09 Planning Phase Requested

- Partner/collaborator/researcher relationships
- Organization structure
- Program leadership
- Business development
- Ethics, legal, privacy, policy frameworks
- Staffing
- Accessibility/policies
- Customer service
- Product acquisition oversight and management
- Program scale-up targets
- Key messages
- Key stakeholder groups
- Plan roll-out/timing
- Marketing objectives and strategies
- Web site development
- Capital investment
- Reimbursement models
- Operating proforma analysis
- ROI
- Milestones
- Actions
- Responsibilities
- Resource requirements
- Sequence/priority

**Bioinformatics/IT Infrastructure**
Step 1: Market Research Conducted for OBBR by NCI’s Office of Market Research and Evaluation

<table>
<thead>
<tr>
<th>Methods</th>
<th>Time Frame</th>
<th>Respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-depth Interviews</td>
<td>July/August 2008</td>
<td>22 (30 invited)</td>
</tr>
<tr>
<td>Online Survey</td>
<td>October 2008</td>
<td>727 (~5000 invited)</td>
</tr>
</tbody>
</table>

**Types of Respondents**
- Academia, NCI grantees (the majority of respondents)
- Federal agencies (NCI, NIH, other)
- Cancer/clinical centers
- Foundations and advocacy groups
- Industry (pharma, biotechnology)

**Themes of Questions**
- Need for quality biospecimens
- Barriers to access
- Consequences of poor access to quality specimens
- Response to the concept of a central biorepository resource
### Initial Survey Findings:
Researchers Are Working in Silos

#### What percentage of your biospecimens come from each of these sources?

<table>
<thead>
<tr>
<th>Source</th>
<th>% Get <em>any</em> from source</th>
<th>Mean % from each</th>
</tr>
</thead>
<tbody>
<tr>
<td>My patients/volunteers</td>
<td>42%</td>
<td>25%</td>
</tr>
<tr>
<td>Other patients in my org</td>
<td>55%</td>
<td>31%</td>
</tr>
<tr>
<td>Other research institutions</td>
<td>41%</td>
<td>17%</td>
</tr>
<tr>
<td>Other medical care facilities</td>
<td>23%</td>
<td>8%</td>
</tr>
<tr>
<td>Commercial U.S. biobank</td>
<td>18%</td>
<td>6%</td>
</tr>
<tr>
<td>Non-profit biobank</td>
<td>12%</td>
<td>4%</td>
</tr>
<tr>
<td>NCI CHTN</td>
<td>12%</td>
<td>4%</td>
</tr>
<tr>
<td>Sources outside the U.S.</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Other sources</td>
<td>1%</td>
<td>1%</td>
</tr>
</tbody>
</table>

- **Collaborative agreements are not widespread**
  - 55% None/Few (0-25%)
  - 23% Some/Many (26-75%)
  - 22% Most/All (76-100%)
Silos Make It Difficult for Investigators to Get What They Need

Ease of Acquiring the **Quantity** of Biospecimens Needed

- Very easy/Easy: 11%
- Somewhat easy: 20%
- Somewhat difficult: 31%
- Difficult/Very difficult: 39%

Ease of Acquiring the **Quality** of Biospecimens Needed

- Very easy/Easy: 8%
- Somewhat easy: 13%
- Somewhat difficult: 32%
- Difficult/Very difficult: 48%
The Science Suffers: Consequences for Investigators

Question Their Data Because of the Quality of Biospecimens

- Never/Rarely (0-25%): 40%
- Sometimes (26-50%): 40%
- Often-Always (51-100%): 20%

Limit Their Scope of Work Due to the Shortage of Quality Biospecimens

- Never/Rarely (0-25%): 19%
- Sometimes (26-50%): 36%
- Often-Always (51-100%): 45%
The Reaction to a National Biobank

How likely would you be to obtain biospecimens from this repository?
- 62% Very likely
- 25% Somewhat likely
- 7% Somewhat unlikely
- 6% Very unlikely

How willing would you be to contribute biospecimens to it?
- 53% Very willing
- 31% Somewhat willing
- 11% Somewhat unwilling
- 5% Very unwilling
Comments about Biospecimen Needs and a National Oncology Repository

• “While it remains an ideal goal at this point, I firmly believe that **high quality specimens are required for all uses** - mine specifically include: identification and validation of biomarkers, establishing clinical cut-offs for test values, establishing normative data for test values, determining predictive value of tests, validating test methods [new and modified], etc.”

• “We don’t know [if high-quality biospecimens are necessary or desirable] because **we aren’t sure how variable our current specimens are and how much this is affecting our outcome.**”

• “It would be great to always have ‘high quality biospecimens’, but **we often have to make do with what we have.**”

• “As basic researchers in a cancer center, **we rely on others to obtain ANY samples, whether high quality or not.** A centralized source for high-quality biospecimens (QA/QC SOPs established and monitored by NCI, for example) would be absolutely ideal.”
Silos Limit Interaction and Progress in Medical Science

caHUB

caHUB Creates Unique Benefits for the Advancement of Science and Medicine

• Builds on NCI’s experiences to date and NBN principles
• Links cancer institutions, researchers, and scientific initiatives
• Benefits (not competes with) other biobanking programs
• Facilitates rapid development and regulatory approval of medical products
• Facilitates standardization and medical implementation of approved products
• Allows direct performance comparisons of different technologies
• Increases efficiency of scientific innovation and knowledge maturation
Silos: Biospecimen Variation Thwarts Innovation in Medical Science

Cannot reproduce original data

Scientific Progress?
Biospecimen Standardization Advances Innovation in Medical Science

Scientific Progress
The Value Proposition:
Biobanks Are Institutions that Amplify Knowledge

- Biological Resource Centers amplify the impact of scientific progress by enabling future generations to build on past discoveries
- Biological Resource Centers fulfill several key functions, including:
  - Authenticating materials to ensure quality
  - Preserving materials having future value over long periods of time
  - Providing Access to materials for the research community
  - Creating Economies of Scale

Developing Cancer Solutions with High-Quality Biospecimens

Milestone: Confirmation of Disease Biomarker

- Analysis of Molecular Features: Hypothesis Generation
- Demonstration of Linkage: Marker of Disease/Disease Feature
- Biomarker Validation

Investment of time and money

- Product Development
  - Diagnostic test (clinical, pathologic)
  - Therapeutic drug
  - Molecular imaging tool
- Product Validation

Any association with specific features: subtype, stage, grade, outcome?
Developing Cancer Solutions with Biospecimens of Unknown Quality

- Analysis of Molecular Features
  - Marker of Disease/Disease Feature
- Biomarker Validation
  - Milestone: Confirmation of Disease Biomarker
  - Product Development
    - Diagnostic test (clinical, pathologic)
    - Therapeutic drug
    - Molecular imaging tool
- Product Validation

**Investment of time and money**

**Pre-analytical artifact?**
**Incorrect identification?**
**Incorrect characterization?**
**Poor product design?**

**STOP**

DO NOT ENTER
The number one problem that companies face in putting together submissions for new diagnostic tests is access to well-annotated human tissue samples that have been properly collected.

» Steven Gutman, M.D., M.B.A., Director, Office of In Vitro Diagnostics, FDA

When it comes to the regulatory process, ... unified and standardized samples would make it much easier to move through the approval process. You simply cannot have proper sample testing and comparative analysis without standardized samples.

» Samir Khleif, M.D., Chief, Cancer Vaccine Section, NCI. Special Assistant to the Commissioner, FDA

If samples were collected in ways that are not determined, it is a challenge for FDA to know what to allow the company to say about sample preparation. If the label is silent on this, how will we know if the data are really reproducible?

» Larry Kessler, Sc.D., Director, Office of Science and Engineering Laboratories CDRH, FDA
“There is an opportunity for the NIH to be the ‘Statue of Liberty’ in creating a vision for how to collect, annotate, store and distribute samples in a standardized way.”

- Steve Gutman, FDA
caHUB Program Design - Functional Areas

Oversight and Governance

Communication and Outreach
- Partnerships Management
- Education and Outreach
- TSS Relations Management
- End User Relations Management

Administration
- Finance - Funding Model (Public-Private)
- Personnel
- Technical and Administrative Operations
- Quality Management
- Policies and Procedures
- Reporting

Ethical / Legal / Policy
- Federal, State, Local Regulations
- DHHS policies
- NIH / NCI policies
- caHUB policies
  - Access
  - Protection
  - Consent

Data Repository
- IT Infrastructure and caBIG
- Clinical Data from NCDB
- Research Data from R&D
- Molecular Analysis Data from Users

R&D
- Evidence-based Best Practices and Quality metrics (BRN)
- Technology development / validation (IMAT)
- Technology integration

Pathology Reference Center
- Sample receiving / quality control
- Sample accessioning – case file / labeling / inventory
- Sample profiling / processing
- Diagnostic confirmation
- Extensive pathology review and reporting
- Sample annotation (data to data repository)
- Sample storage and end user distribution

Services/Tools
- Best Practices
- Biospecimen Science Training
- Biospecimen Resource Evaluation Tools
- Specimen Locator Tool
- Biospecimen Research Database (BRD)
Planning Phase Working Groups to Support Development of Functional Areas

- Administration
- Partnerships Management
- Ethical, Legal, Policy
- Informatics and Data Management
- Collection, Processing, Storage of Biospecimens
- Emerging Tools and Technologies

- Patient Advocacy
- Research and Development
- Annotation of Pre-Analytical Variables
- Annotation of Clinical Data
- Experimental Design
- Acquisition of Normal Tissue
- Quality Metrics
- SOP Development
caHUB Phase 1: Planning

FY09 Budget: $1,145,000
Sustainable Funding Models for caHUB

- For caHUB to be **cost-effective, efficient** and **sustainable** over the long-term, it must have a funding model that:
  - Engages the resources of private industry and philanthropy through a public-private partnership
  - Minimizes or eliminates reliance on external funding through a sound cost-recovery program
  - Maintains efficiency and effectiveness through process automation, virtual networking, and technical innovation
A Sustainable Funding Model for caHUB: Public-Private Partnership

- Consulting firm engaged to develop a sustainable, cost-recovery funding model

- Public-private partnership envisioned during or following demonstration phase
  - OBBR working with NIH Public-Private Partnerships Office
  - OBBR working with Foundation for the NIH (FNIH)

- Public-Private Partnership
  - Government and non-government (industry, advocacy, academic) represented
  - Governance and decision-making includes government, but not limited to government
    - NCI gives up some ownership (negotiated)
The Cancer Human Biobank (caHUB): Advancing the Vision of Personalized Medicine

Carolyn C. Compton, M.D., Ph.D.
Director, Office of Biorepositories and Biospecimen Research
Acting Director, Office of Technology and Industrial Relations

Presentation to the National Cancer Advisory Board
December 9, 2008
The Cancer Human Biobank (caHUB): Additional Information

Carolyn C. Compton, M.D., Ph.D.
Director, Office of Biorepositories and Biospecimen Research
Acting Director, Office of Technology and Industrial Relations

Presentation to the National Cancer Advisory Board
December 9, 2008
Lessons Learned from TCGA - Top 5 Sources of GBM Failure

• Matched normal germline DNA controls (blood or other) lacking
• Insufficient tumor cellularity in samples
  – Tumor cellular composition too low
  – % necrosis too high
• Specimen size too small
  – Insufficient for minimum required DNA/RNA for all analyses
• Molecular quality insufficient
  – QC failure of DNA or RNA
  – Insufficient amount
• Clinical data incorrect: Tumor not primary disease
  – Samples derived from recurrent, i.e. previously treated GBMs
    (confounding issue: Rx-related effects)
<table>
<thead>
<tr>
<th>Institute</th>
<th>PI</th>
<th>Platform(s)</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broad Institute of MIT and Harvard</td>
<td>Meyerson</td>
<td>Affymetrix U133 A HTS: transcription; SNP 6.0: copy number alteration</td>
<td></td>
</tr>
<tr>
<td>Lawrence Berkeley National Laboratory</td>
<td>Gray</td>
<td>Affymetrix Exon 1.0 ST: transcription profiling</td>
<td></td>
</tr>
<tr>
<td>Memorial Sloan-Kettering</td>
<td>Ladanyi</td>
<td>Agilent 244K “oligo” array: chromosomal copy number alteration</td>
<td>Custom Agilent array: chromosomal translocations</td>
</tr>
<tr>
<td>U. of North Carolina</td>
<td>Perou</td>
<td>Agilent 244K “oligo” and microRNA arrays: transcription profiling</td>
<td></td>
</tr>
<tr>
<td>Harvard</td>
<td>Kucherlapati</td>
<td>Agilent 244K “oligo” array: copy number alteration</td>
<td>Development of polony-based serial analysis of gene expression</td>
</tr>
<tr>
<td>Stanford</td>
<td>Richard Myers, PhD</td>
<td>Illumina 550k Infinium SNP chip array: copy number alteration</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins</td>
<td>Baylin</td>
<td>Epigenetic analyses: Illumina Golden Gate platform: methylation</td>
<td></td>
</tr>
<tr>
<td>Institute</td>
<td>PI</td>
<td>Platform(s)</td>
<td>Other</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Baylor College of Medicine Sequencing Center</td>
<td>Richard Gibbs, PhD</td>
<td>Sanger sequencing of PCR amplified fragments</td>
<td>Illumina Inc, 454 Life Sciences</td>
</tr>
<tr>
<td>Broad Institute of MIT and Harvard, Cambridge, MA</td>
<td>Eric Lander, PhD</td>
<td>Sanger sequencing of PCR amplified fragments</td>
<td>Illumina Inc, others</td>
</tr>
<tr>
<td>Washington University School of Medicine Sequencing Center</td>
<td>Richard Wilson, PhD</td>
<td>Sanger sequencing of PCR amplified fragments</td>
<td>Illumina Inc, 454 Life Sciences</td>
</tr>
</tbody>
</table>
caHUB – ORGANIZATIONAL STRUCTURE

**Policy**
- Oversight and Governance:
  - Department of Health and Human Services
  - National Institutes of Health
  - National Cancer Institute
  - United States Congress
  - National Cancer Program
  - Cancer Bill
  - Other health-related legislation

**Strategy**
- Program Design and Strategic Management:
  - OBBR Program Staff

**Process**
- Project Development and Implementation:
  - Administration Working Group
- Protocol and SOP Development:
  - Collection, Processing, and Storage Working Group
  - Comprehensive Data Resource Working Group

**Learning and Growth**
- Research and Development:
  - BRN, IMAT, Emerging Technologies and Tools Working Group
- Communications and Outreach:
  - OBBR program staff
  - NCI OCE, OAR, OGCR
  - Contributions from Working Groups

**Partnerships and Collaborations**
- Disease-based Interest Groups
- Private Foundations
- Other Government Agencies
- Biotechnology and Pharmaceutical Industries
- United States Congress
- National Cancer Program
- Cancer Bill
- Other health-related legislation
National Biospecimen Network Pilot Study

- Carried out in 2005-2006 among 11 prostate cancer SPORE sites
- Challenges posed by process variation among study sites:
  - Different procedures for collecting tissues
  - Different procedures for obtaining informed consent
  - Different informatics systems that were not interoperable
  - Lack of information necessary to identify sources of variation
  - Lack of ability/authority of participants to institute procedural changes within their institutions that would be needed to harmonize across sites
- Pilot terminated
- “Rule book” developed: NCI’s Best Practices for Biospecimen Resources
caHUB access polices will be:

- Guided by the principles outlined in the *NCI Best Practices for Biospecimen Resources*
- Based on merit and nature of the scientific investigation
- Adapted to meet the needs of the research community
- Developed to ensure compliance with all applicable Federal and State privacy and human subjects regulations and statutes
- Developed to ensure transparent, timely, equitable, and appropriate access
- Transparent and publically available
Centralized source of standardized human samples

- Duplicate samples allow direct comparisons of data from different scientific initiatives / oncology product development steps
- "Big science" data linked through the specimens (envision genomic, epigenomic, transcriptomic, and proteomic data linkage)
- Product (therapeutic; diagnostic) and technology development /standardization/regulatory approval all streamlined
- Direct product-to-product performance comparisons enabled
- Standardized reference specimens ("yardstick of truth") for FDA approval / medical implementation

Leverage NCI’s investment in other programs, create unprecedented return on investment and rapid acceleration of scientific knowledge
caHUB Goals: Accelerating the Vision of Personalized Medicine

• Develop and disseminate evidence-based standard operating procedures
• Document and evaluate the current status and quality of human specimens available for research through extensive market research
• Identify strengths in existing specimen demand-supply chain and identify areas of opportunity for further development
• Engage in contractual relationships with tissue source sites to acquire needed biospecimen types
• Support and sponsor research in biospecimen science to further refine and improve standard biobanking practices
• Support and sponsor innovative technology development in biobanking and integration of new and existing technologies into current biobanking practice
• Develop and disseminate tools and resources to support new and existing biospecimen resources
• Engage in public education awareness activities, and support the development of training programs in biospecimen science
Life After Regulatory Approval:  
Biospecimens Throughout a Product’s Lifespan

Diagnostic Tests / Laboratory Assays

High-Quality Standardized Biospecimens

Define standards
- Test execution
- Tolerance for variation
- Test performance

Daily execution
- Quality Assessment
- Quality Control
- Calibration

- Decreased false negatives and false positives
- Improved Standard of Care
HER2 (ERBB2) gene is amplified in ~ 20% of breast cancers

HER2 over-expression ("positive" status): important measure of clinical outcome and recommended therapy

Clinical testing for HER2 status:
- Formalin-fixed paraffin-embedded cancer tissue*:
  - Immunohistochemical test (0-3+)
  - 2+ cases: FISH
- Pathologist uses scoring system to report status

Positive result triggers therapy: ~$55K/year

False-positive: risk of cardiotoxicity, no clinical benefit

False-negative: missing potentially beneficial treatment

Genentech estimated 5,000 false positives and 7,000 false negatives per year: problem not the assay but where (proficiency) and on what (specimen quality) the assay is performed.

Standards for specimen handling (type of fixative; length of fixation) not standardized by CAP until 2008
Stem cells harvested from patient → frozen → reintroduced after chemotherapy

- SOP altered by lab director to shorten freeze time
- New SOP not validated
- Result: > 20% mortality rate
- Lawsuit alleges negligence in quality control of stem cells in the biorepository
National Cancer Database (NCDB)

- Joint program of Commission on Cancer (COC) of the American College of Surgeons and the American Cancer Society
  - Main goal: Assessment of quality of cancer care
- Collects data from 75% of newly diagnosed cancer cases
  - >1400 COC approved cancer programs, 80% community/other
  - Data: Patient characteristics, Pathology, Staging, Treatment, Outcome, Co-morbidity
- Significant data collection and reporting infrastructure
  - Requirement to follow up on care outside reporting institution
  - Standardized data (Facility Oncology Registry Data Standards [FORDS] manual)
  - Data managed by trained registrars
  - Quality control mechanisms
- Known issues
  - Data access agreements would need revision for HUB sources
  - Completeness of data on adjuvant therapy
    - caHUB adds additional impetus for follow-up
  - Partnering with NCDB on plan to address issues
Comments about Biospecimen Standards and a National Oncology Repository

- “We are wasting a lot of resources with low quality biospecimens. For example, in a project measuring various phospho-proteins by IHC, only 1/29 specimens was of sufficient quality (as judged by internal controls). In another project 1/6 specimens was satisfactory. The quality is very problematic and highly variable and absolutely differs according to the biomarkers of interest. For examples, all these specimens are adequate for RNA measurements, but are NOT adequate”

- “We perform advanced technology development on specimens and have no use for samples where the integrity of the DNA or the RNA or the protein in them is unknown before we start. Since such information is almost never known or even spot-checked for banked specimens, we inevitably perform such QC analysis on our own, since frankly, the quality of most biorepository materials we are aware of in the US is highly suspect.”

- “I am developing biomarkers. For detection I need disease vs. healthy; for diagnosis I need disease AND confounding diseases; for prediction of outcome I need follow-up; for prediction of response I need treatment data. It is a shame that an established procedure PLUS an appropriate bioinformatics package PLUS SOPs for biobank management has not yet been developed, so everyone has to design his own (e.g., Northwestern U, Fox Chase, Fred Hutch, etc.)”
caHUB (Cancer HUMAN Biobank)

caBIG®

American College Of Surgeons Commission On Cancer
Certifies quality of care

- NCI-Funded Centers
  - Academic Centers
  - NCCCP
- US Military Cancer Center
- Other

National Cancer Database (NCDB)

Pathology Reference Center

Comprehensive Data Bank

Training / Education

R&D

- Advocacy Groups
- Biotech / Pharma / Diagnostics

End-Users

Contributors

Normal Specimens

Surgery Groups: Plastic, Trauma, Transplant

Rapid Autopsy Programs

Translational Research Initiatives

FDA / NIST/ CDC

Disease Specimens:
Cancer and Pre-cancerous Conditions

caHUB: UNIQUE • HIGH QUALITY SPECIMENS • HIGH QUALITY DATA • FROM PTS WHO RECEIVED HIGH QUALITY CARE
What Is caHUB?

A unique, centralized, non-profit public resource that will ensure the adequate and continuous supply of human biospecimens and associated data of measurable, high quality acquired within an ethical framework.